Heart Failure and Peritoneal Ultrafiltration

This study has been terminated.

(Enrollment)

Sponsor:

Information provided by:

Baxter Healthcare Corporation

ClinicalTrials.gov Identifier:

NCT00368641

First received: August 23, 2006

Last updated: April 30, 2009

Last verified: April 2009

History of Changes

Results First Received: April 30, 2009

Study Type:	Interventional
Study Design:	Allocation: Randomized; Endpoint Classification: Safety/Efficacy Study; Intervention Model: Parallel Assignment; Masking: Open Label; Primary Purpose: Treatment
Condition:	Congestive Heart Failure
Intervention:	Drug: Extraneal

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
12 sites were active to enroll subjects from March 2, 2007 through February 29, 2008

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Subjects were required to meet all inclusion and no exclusion criteria for study participation

Reporting Groups

	Description
Intervention Group	Addition of peritoneal ultrafiltration
Standard Therapy	Standard therapy for CHF

Participant Flow: Overall Study

	Intervention Group	Standard Therapy
STARTED	6	6
COMPLETED	0 ^[1]	0 ^[1]
NOT COMPLETED	6	6
Adverse Event	2	1
Death	1	0
Withdrawal by Subject	1	0
Sponsor decision to terminate study	2	5

[1]	study was terminated prior to completion of treatment period

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
Intervention Group	Addition of peritoneal ultrafiltration
Standard Therapy	Standard therapy for CHF
Total	Total of all reporting groups

Baseline Measures

	Intervention Group	Standard Therapy	Total
Number of Participants [units: participants]	6	6	12
Age [units: participants]
<=18 years	0	0	0
Between 18 and 65 years	0	2	2
>=65 years	6	4	10
Age [units: years] Mean ± Standard Deviation	77.8 ± 4.1	70.7 ± 13.1	74.3 ± 10.0
Gender [units: participants]
Female	1	1	2
Male	5	5	10
Region of Enrollment [units: participants]
United States	2	2	4
Canada	3	3	6
Belgium	1	1	2

Outcome Measures

1. Primary:

All-cause Hospitalization (Unadjusted) [ Time Frame: 6 to 24 months ]

Show Outcome Measure 1

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
The number of subjects enrolled & duration of therapy were insufficient to complete the planned efficacy analyses & to draw any conclusion regarding all-cause hospitalization rates in both intervention and standard therapy arms.

Results Point of Contact:

Name/Title: Bruce Culleton, MD
Organization: Baxter Healthcare
phone: 800-422-9837
e-mail: onebaxter@baxter.com

No publications provided

Responsible Party:	Bruce Culleton, Sr. Medical Director, Baxter Healthcare Corporation
ClinicalTrials.gov Identifier:	NCT00368641 History of Changes
Other Study ID Numbers:	25885
Study First Received:	August 23, 2006
Results First Received:	April 30, 2009
Last Updated:	April 30, 2009
Health Authority:	United States: Food and Drug Administration Canada: Health Canada Australia: Department of Health and Ageing Therapeutic Goods Administration Belgium: The Federal Public Service (FPS) Health, Food Chain Safety and Environment

To Top